- European authorities' antitrust probe will likely push the company to change its marketing practices, which allegedly hindered competitors from introducing generic versions of Teva's Copaxone®.
- With the recent commercialization of Belrapzo®, a superior substitute for Teva's Bendeka®, sales from this drug will probably suffer in the coming quarters.
- Increased debt combined with competitive dynamics in Teva's branded and generic segments, and a weak balance sheet leads us to conclude that the company will not rush to reinstate dividends.
For further details see:
Teva Pharmaceutical's Ice-Cube Business Model